[go: up one dir, main page]

WO2006079999A3 - Induction d'un nouvel etat psychique a l'aide d'un agoniste de 5-ht2a et d'un antagoniste de nmda - Google Patents

Induction d'un nouvel etat psychique a l'aide d'un agoniste de 5-ht2a et d'un antagoniste de nmda Download PDF

Info

Publication number
WO2006079999A3
WO2006079999A3 PCT/IB2006/051080 IB2006051080W WO2006079999A3 WO 2006079999 A3 WO2006079999 A3 WO 2006079999A3 IB 2006051080 W IB2006051080 W IB 2006051080W WO 2006079999 A3 WO2006079999 A3 WO 2006079999A3
Authority
WO
WIPO (PCT)
Prior art keywords
mind
induction
nmda antagonist
ht2a agonist
novel
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IB2006/051080
Other languages
English (en)
Other versions
WO2006079999A2 (fr
Inventor
Frederik H Barth
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to PCT/IB2006/051080 priority Critical patent/WO2006079999A2/fr
Publication of WO2006079999A2 publication Critical patent/WO2006079999A2/fr
Publication of WO2006079999A3 publication Critical patent/WO2006079999A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Addiction (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Il a été découvert que l'administration, à un être humain, d'un agoniste de 5-HT2A hallucinogène en combinaison avec un antagoniste de NMDA induisait un état nouveau et particulier du psychisme humain. Cet état psychique est non psychotique et bénin. L'induction de cet état nouveau et particulier du psychisme humain peut être utilisé à des fins thérapeutiques, récréatives et à d'autres fins utiles.
PCT/IB2006/051080 2006-04-09 2006-04-09 Induction d'un nouvel etat psychique a l'aide d'un agoniste de 5-ht2a et d'un antagoniste de nmda Ceased WO2006079999A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
PCT/IB2006/051080 WO2006079999A2 (fr) 2006-04-09 2006-04-09 Induction d'un nouvel etat psychique a l'aide d'un agoniste de 5-ht2a et d'un antagoniste de nmda

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/IB2006/051080 WO2006079999A2 (fr) 2006-04-09 2006-04-09 Induction d'un nouvel etat psychique a l'aide d'un agoniste de 5-ht2a et d'un antagoniste de nmda

Publications (2)

Publication Number Publication Date
WO2006079999A2 WO2006079999A2 (fr) 2006-08-03
WO2006079999A3 true WO2006079999A3 (fr) 2007-04-26

Family

ID=36740888

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2006/051080 Ceased WO2006079999A2 (fr) 2006-04-09 2006-04-09 Induction d'un nouvel etat psychique a l'aide d'un agoniste de 5-ht2a et d'un antagoniste de nmda

Country Status (1)

Country Link
WO (1) WO2006079999A2 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12459965B2 (en) 2017-10-09 2025-11-04 Compass Pathfinder Limited Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their use
GB2571696B (en) 2017-10-09 2020-05-27 Compass Pathways Ltd Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced
EP3955918A1 (fr) 2019-04-17 2022-02-23 COMPASS Pathfinder Limited Procédés pour traiter les troubles neurocognitifs, la douleur chronique, et pour réduire l'inflammation
AU2021327136A1 (en) 2020-08-18 2023-02-16 Cybin Irl Limited Therapeutic phenethylamine compositions and methods of use

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992006973A1 (fr) * 1990-10-15 1992-04-30 Pfizer Inc. Derives d'indole
US5902815A (en) * 1996-09-03 1999-05-11 Washington University Use of 5HT-2A serotonin agonists to prevent adverse effects of NMDA receptor hypofunction
WO2006042249A2 (fr) * 2004-10-08 2006-04-20 Neuromolecular Pharmaceuticals, Inc. Methodes et compositions de traitement de la douleur de migraine

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992006973A1 (fr) * 1990-10-15 1992-04-30 Pfizer Inc. Derives d'indole
US5902815A (en) * 1996-09-03 1999-05-11 Washington University Use of 5HT-2A serotonin agonists to prevent adverse effects of NMDA receptor hypofunction
WO2006042249A2 (fr) * 2004-10-08 2006-04-20 Neuromolecular Pharmaceuticals, Inc. Methodes et compositions de traitement de la douleur de migraine

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
FARBER NURI B ET AL: "Serotonergic agents that activate 5HT2A receptors prevent NMDA antagonist neurotoxicity", NEUROPSYCHOPHARMACOLOGY, vol. 18, no. 1, January 1998 (1998-01-01), pages 57 - 62, XP002396767, ISSN: 0893-133X *
WEST WILLIAM B ET AL: "Antagonism of a PCP drug discrimination by hallucinogens and related drugs", NEUROPSYCHOPHARMACOLOGY, vol. 22, no. 6, June 2000 (2000-06-01), pages 618 - 625, XP002396768, ISSN: 0893-133X *

Also Published As

Publication number Publication date
WO2006079999A2 (fr) 2006-08-03

Similar Documents

Publication Publication Date Title
WO2008034041A3 (fr) Combinaisons thérapeutiques
PL2044076T3 (pl) Sposób wytwarzania asenapiny i związki pośrednie do stosowania w tym sposobie
WO2007135461A3 (fr) Compositions pharmaceutiques et méthodes d'application
WO2007073486A3 (fr) Procedes et compositions pour l'administration d'agents actifs a proprietes pharmacologiques ameliorees
WO2009063222A3 (fr) Compositions solides
ZA200807879B (en) Use of bifidobacterium longum for the prevention and treatment of inflammation
WO2007106537A3 (fr) Aminoquinolones utilisées comme inhibiteurs de la gsk-3
WO2006044505A3 (fr) Composes pour la suppression de mutations non-sens et procedes d'utilisation associes
WO2008053444A3 (fr) Méthodes visant à traiter un trouble respiratoire au moyen d'un traitement probiotique
WO2008131057A3 (fr) Préparations à libération contrôlée d'analgésiques opioïdes et non opioïdes
NZ577392A (en) Use of 3-alpha-androstanediol, optionally in combination with a 5-ht1a agonist, in the treatment of sexual dysfunction
WO2010003992A8 (fr) Combinaison d'un antagoniste de c-met et d'un composé aminohétéroaryle pour le traitement d'un cancer
JO2721B1 (en) Derivatives of artemisia plant and its preparations and therapeutic applications
WO2007130822A3 (fr) Modulateurs des récepteurs mglur5 iii
WO2009035634A3 (fr) Cyanoaminoquinolones et tétrazoloaminoquinolones en tant qu'inhibiteurs de gsk-3
WO2009018226A3 (fr) Combinaisons pharmaceutiques
ZA201001085B (en) Indol-2-one derivatives disubstituted in the 3-position,preparation thereof and therapeutic use thereof
WO2005107810A3 (fr) Formulations pharmaceutiques et leurs utilisations dans le traitement du dysfonctionnement sexuel chez la femme
SG10201408374WA (en) Therapeutic Combinations Of Theobromine And An Antihistamine
WO2007133796A3 (fr) Procédés et compositions de traitement de l'apnée du sommeil
ZA201000581B (en) 1,2,3,4-tetrahydropyrrolo[1,2-a]pyrazine-6-carboxamide and 2,3,4,5-tetrahydropyrrolo[1,2-a][1,4]-diazepine-7-carboxamide derivatives,preparation and therapeutic use thereof
IL198481A0 (en) Pyrrole derivatives, preparation use of the same in therapy
WO2011058373A3 (fr) Association médicamenteuse comprenant de la théobromine et son utilisation en thérapie
MX2009011294A (es) Combinacion de farmacos y su uso en el tratamiento de la perdida muscular.
WO2006079999A3 (fr) Induction d'un nouvel etat psychique a l'aide d'un agoniste de 5-ht2a et d'un antagoniste de nmda

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 06727863

Country of ref document: EP

Kind code of ref document: A2

122 Ep: pct application non-entry in european phase

Ref document number: 06727863

Country of ref document: EP

Kind code of ref document: A2